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The purpose of this literature review was to compare 
the methodology used in the most recently published cost-
effectiveness studies of antihypertensive treatments, and
to identify methodological strengths and weaknesses that
indicate the study’s potential as a useful, decision-making
tool. Based on the results of a search of several databases,
spanning the years 1995 to 2000, 10 cost-effectiveness
studies were identiﬁed. Although the majority of the
studies reported their cost-effectiveness ratio in “costs per
year of life gained,” the studies also considered a varying
range of components including additional end points. The
methodology used to measure effectiveness, the cost vari-
ables included, and the characteristics of the patient pop-
ulation varied signiﬁcantly across studies. Due to this lack
of conformity, it would be difﬁcult, if not impossible, to
compare the results and draw conclusions about the 
relative cost-effectiveness of different types of antihyper-
tensive drug therapies. This lack of uniform comparison
across studies is likely to draw criticism from both the
clinical and health-care decision-making communities.
Future studies within this ﬁeld should be thorough and
useful for decision making. It is suggested that short-term
outcomes should include systolic and diastolic blood
pressure measurements and long-term outcomes should
include end points such as myocardial infarction, stroke,
congestive heart failure and renal events. Other positive
outcomes such as a more favorable side-effect proﬁle,
should be used to enhance the primary outcomes. Addi-
tionally, when subpopulations are considered in submod-
els, studies should address the issue of generalizability.
Cost calculations should be transparent and related to the
perspective of the study. Modeling the cost-effectiveness
of a drug may be an acceptable method provided that
data sources and assumptions are valid and transparent.
Keywords: cost-effectiveness, decision making, guide-
lines, hypertension.
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ABSTRACT
Introduction
Cost-effectiveness analysis (CEA) of a drug treat-
ment provides information on the associated out-
comes including costs and the gained clinical
beneﬁts of the treatment. This information can be
useful in decision-making processes, particularly in
cases where limited resources need to be allocated
among a variety of different drug treatments. The
cost-effectiveness (CE) ratios calculated in a CEA
can be ranked in order such that a decision maker
can select the intervention with the lowest cost per
clinical beneﬁts gained [1]. This approach seems
most logical and beneﬁcial for making treatment
decisions regarding the use of numerous agents
available for hypertension therapy. Although this
review focuses on current CE analyses of hyperten-
sion treatments, it may also provide valuable insight
into the management of overall cardiovascular risk,
rather than just the treatment of hypertension.
Approximately 48 million Americans suffer from
hypertension, which is about one ﬁfth of the total
US population [2]. Hypertension is deﬁned as sys-
tolic blood pressure (SBP) of 140mmHg or greater,
diastolic blood pressure (DBP) of 90mmHg or
greater, or ongoing therapy with antihypertensive
medication for a previous diagnosis of hypertension
based on similar blood pressure criteria. Stage 1
hypertension is deﬁned as SBP 140–159mmHg or
DBP 90–99mmHg, stage 2 as SBP 160–179mmHg
or DBP 100–109mmHg and stage 3 as SBP ≥
180mmHg or DBP ≥ 110mmHg [3]. It should be
noted that in 1998, hypertension entered the list of
the 15 leading causes of death in the United States
[4]. This condition is one of the major factors con-
tributing to the development of cardiovascular dis-
eases (CVD). CVD have been the leading cause of
death for many years and in 1998 accounted for
31% of total mortality in the United States [4]. The
combined direct and indirect cost of CVD and
stroke in the United States in 2000 was estimated
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at $326.6 billion and accounted for the largest pro-
portion of health care spending [5].
Reports from various stakeholder communities
have argued that the current methods for calculat-
ing and reporting CE results for decision making are
suboptimal [6–8]. The variability among the studies
is a reﬂection of: 1) the fact that this is a new area
of research; 2) the inherent variability within clini-
cal data and clinical trials; and 3) the reality that
there is a demand for health economic data early in
the development process for pricing and reimburse-
ment, while there is a need for long-term studies,
particularly for chronic diseases. To address general
issues related to pharmacoeconomic studies, The US
Public Health Service set up a Panel on Cost-
Effectiveness in Medicine and published a supple-
mentary book, which summarizes discussions and
recommendations set by the panel [1]. The
Academy of Managed Care Pharmacy has pub-
lished a set of guidelines for submission of clinical
and economic data in support of formulary consid-
erations to facilitate the use of pharmacoeconomic
information for decision making [9]. Johannesson
and Johnsson examined various methodological
approaches that speciﬁcally affect the results of
antihypertensive CEAs [10]. They found that results
obtained from cost-effectiveness and outcomes
research studies in the ﬁeld of hypertension must be
interpreted with caution. As the ﬁeld of pharma-
coeconomics is evolving, the objective of this paper
is to analyze the most recent CE studies of treat-
ments for hypertension. We assumed that these
studies were meant to be informative to the 
decision-making process with respect to antihyper-
tensive treatment options. Our intention was not to
state whether the CEA was poor or strong but
rather to identify those studies that actually per-
formed a true CEA, i.e., considered both costs and
effectiveness of hypertension treatment, and to
identify differences and similarities across the study
analyses.
Given the prevalence of hypertension and the
cost burden that this disease poses to society if left
untreated, many scholarly papers address the CE of
hypertension treatments. Therefore, the ﬁrst objec-
tive of this article is twofold: ﬁrst to identify the
number of articles that discuss or mention the CE
of hypertension treatment, and second, to identify
how many actually performed a CEA.
The second objective is to outline and discuss 
the methodology of the published CEA analyses of
hypertension treatments. The third objective is to
consider their limitations with respect to their inﬂu-
ence on the decision-making process and the inter-
pretation of results across studies. The overall goal
is to provide guidance so that future CEAs of hyper-
tension treatments will provide more optimal infor-
mation for clinicians and other decision makers
when choosing an antihypertensive treatment. It
should be noted that this review focuses on the cal-
culation and reporting of the cost-effectiveness 
estimates rather than on the actual numeric values
derived from the cost-effectiveness analyses. There-
fore this review should not be used to assess the
cost-effectiveness of different antihypertensive
drugs.
Methods
A search of the literature published between the
years 1995 to 2000 was conducted using the fol-
lowing terms: hypertension (and) cost-effectiveness
(or) economics. The following databases were con-
sulted for this particular search: Medline; Health
Star; International Pharmaceutical Abstracts; EBM
reviews (Cochrane database); National Health 
Sciences Center for Review and Dissemination, 
University of York.
The quality of the cost-effectiveness calculation
depends on the methodology applied and the accu-
racy and relevance of data used to calculate the
beneﬁt and cost measures. The following sections
report the search result according to the type of
patients studied, how effectiveness was measured or
derived, how costs were measured, how the overall
cost-effectiveness ratio was reported and what end
points were used.
Results
Eighty-nine articles were identiﬁed as a result of 
our searches across various databases. Of these, 59
articles either discussed or mentioned the cost-
effectiveness of hypertension treatment in various
contexts but did not perform an actual cost-
effectiveness analysis, and 19 articles were pure cost
studies, which analyzed the cost of hypertension
treatment within different clinical settings. These 78
articles were therefore excluded from our selection.
The remaining 11 articles were true pharmacoeco-
nomic studies. One of the 11 studies analyzed 
the cost-effectiveness of the diagnosis and therapy
of renovascular hypertension [11]. This study was
not included in the review since it focused primar-
ily on the cost-efﬁcacy of several different screening
tests for renovascular hypertension. Therefore, only
the 10 most relevant cost-effectiveness studies of
drug treatment for hypertension comprised the
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focus of this literature review [12–21]. These 10
studies are denoted STUDY1–10.
A problematic outcome of our analysis is the fact
that there is considerable variation across antihy-
pertensive CEA studies with respect to types of
patients examined, the measures of effectiveness
and costs used, and the way in which cost-
effectiveness ratios were calculated and reported.
Patient Population
Table 1 presents the characteristics of the popula-
tion in the clinical trials and/or the hypothetical
population included in the models. The information
in Table 1 is what was found in the corresponding
CE study, which may not be as complete as what
was described in the original clinical trial. Some of
these studies presented the characteristics of the
trial patients so that the reader did not have to go
back to the original trial, while others did not. The
studies differed in terms of both demographic and
clinical characteristics. Some studies examined
actual patients, while others modeled hypothetical
cohorts of patients. Four of the cost-effectiveness
studies based their work on clinical trials, which
implies that they obtained treatment effects, inci-
dence data and survival data from these trials
[12–15]. STUDY2 [13] and STUDY3 [14] random-
ized their patients into groups of treatments with
drug A vs. drug B and tight vs. less tight blood 
pressure control, respectively. STUDY1 [12] and
STUDY4 [15] obtained measures of treatment effec-
tiveness from clinical trials in which patients were
randomized according to different diastolic blood
pressure target groups and into groups of treatment
vs. no treatment, respectively. The patient popula-
tions in the clinical trials all had concomitant dis-
eases, although STUDY3 [14] excluded patients if
they had a cardiovascular or cerebrovascular event
within the 6-month period preceding the start of the
trial.
In studies where researchers combined data from
different sources and used modeling to project life
expectancy, existing risk factors were accounted 
for by using a variety of techniques [17–19]. In one
model it was assumed that hypertensive patients did
not initially have any concomitant diseases [19].
This was also true for the model used in STUDY 5
except that the patients had type-2 diabetes [16].
STUDY9 [20] and STUDY10 [21] did not provide
information about the population, but STUDY9
categorized patients as having moderate to severe
hypertension or mild hypertension.
The majority of studies deﬁned hypertension
based on the diastolic blood pressure, which was
used as an inclusion criteria [12,13,17,18,20,21].
STUDY8 [19] focused on the effect of treatment on
systolic blood pressure alone, and the remaining
studies, STUDY4 [15] and STUDY5 [16], required
both elevated diastolic and systolic blood pressure
measurements for inclusion (Table 1).
Effectiveness
With respect to the effectiveness component,
STUDY2 [13] and STUDY3 [14] derived treatment
effectiveness directly from the trial results (Table 2).
STUDY1 [12] derived treatment effectiveness from
the Hypertension Optimal Treatment (HOT) study
and STUDY5 [16], from the Studies of Left 
Ventricular Dysfunction (SOLVD) trials, which
included two clinical trials: the Treatment Trial, and
the Prevention Trial. The remaining studies utilized
results from several different clinical trials to esti-
mate the treatment effect of various antihyperten-
sive drugs [16–21]. Most of the studies discounted
both the beneﬁts and costs except for STUDY1 [12],
which discounted the beneﬁts but not the costs,
since costs were annual. Neither beneﬁts nor costs
were discounted in STUDY3 [14] or STUDY10 [21]
because they had short follow up periods, as indi-
cated in Table 3.
Studies that used life years gained in the outcome
measure generated life expectancy and/or survival
estimate through the use of modeling. The models
incorporated the treatment effect and the incidence
data to estimate hypothetical longevity, assuming
that a person was on lifelong antihypertensive treat-
ment. Several studies used the Framingham risk
equations to determine the pretreatment risk of 
cardiovascular disease and stroke, as indicated in
Table 2 [17–20]. STUDY2 [13] used the differences
in hazard rates between the two trial groups and
assumed that the groups would have identical
hazard rates beyond the trial [13]. Another study
estimated the annual survival probabilities using
data from two clinical trials and created a survival
curve from which the life expectancy was estimated
from the area under the curve [15]. STUDY4 [15],
STUDY7 [18], and STUDY8 [19] adjusted the
achieved life years gained for quality of life by
applying a utility measure (Table 2).
Costs
Table 3 presents the cost variables included in 
the cost-effectiveness measure and the correspond-
ing references. Only STUDY3 [14] derived costs
entirely from the resources used during the clinical
trial. STUDY2 [13] used resource units from the
clinical trial but added cost information from
362 Mullins et al.
Ta
bl
e 
1
St
ud
y 
po
pu
la
tio
n 
ch
ar
ac
te
ri
st
ic
s 
(in
fo
rm
at
io
n 
fo
un
d 
in
 C
E 
st
ud
y)
St
ud
y 
no
.
1 
[1
2]
2 
[1
3]
3 
[1
4]
4 
[1
5]
5 
[1
6]
Ty
pe
 o
f 
po
pu
la
tio
n
C
C
C
C
H
N
N
ot
 p
ro
vi
de
d
11
48
12
0
19
17
N
A
A
ge
,m
ea
n 
ye
ar
s 
(S
D
)
N
ot
 p
ro
vi
de
d
56
 (
8.
1)
55
A
pp
ro
x.
61
 (
9.
4)
50
–5
9,
60
–6
9,
70
–7
9,
80
–8
9
Ba
se
lin
e 
D
BP
 m
m
H
g
N
ot
 p
ro
vi
de
d
≥9
0 
(n
o 
tr
ea
tm
en
t)
95
–1
15
A
pp
ro
x.
86
.2
 (
8.
9)
90
(S
D
)
Ba
se
lin
e 
SB
P 
m
m
H
g
N
o 
fo
cu
s 
on
 S
BP
≥1
60
 (
no
 t
re
at
m
en
t)
N
o 
fo
cu
s 
on
 S
BP
A
pp
ro
x.
14
4.
4 
(1
2.
6)
14
0
(S
D
)
≥1
50
 (
on
 t
re
at
m
en
t)
Ex
cl
ud
ed
 if
 >
20
0
M
al
e 
%
N
ot
 p
ro
vi
de
d
54
39
A
pp
ro
x.
85
N
ot
 c
on
si
de
re
d
R
ac
e 
%
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
A
pp
ro
x.
W
:7
9,
B:
14
,
N
ot
 c
on
si
de
re
d
O
:7
Pr
io
r 
M
I 
%
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
Ex
cl
ud
ed
 if
 M
I 
w
ith
in
 6
A
pp
ro
x.
70
N
on
e
m
on
th
s 
pr
io
r 
to
 s
tu
dy
st
ar
t
Ba
se
lin
e 
C
H
D
 %
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
Ex
cl
ud
ed
 if
 C
A
BG
,C
H
F 
6
A
pp
ro
x.
26
–7
4
N
on
e
m
on
th
s 
pr
io
r 
to
 s
tu
dy
 
st
ar
t
Ba
se
lin
e 
C
V
D
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
Ex
cl
ud
ed
 if
 T
IA
 6
 m
on
th
s
N
ot
 p
ro
vi
de
d
N
on
e
pr
io
r 
to
 s
tu
dy
 s
ta
rt
Ba
se
lin
e 
re
na
l d
is
ea
se
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
N
ot
 p
ro
vi
de
d
N
on
e
M
en
tio
n 
of
 d
ia
be
te
s
N
o
A
ll 
ha
d 
ty
pe
 2
N
o
N
o
A
ll 
ha
d 
ty
pe
 2
M
en
tio
n 
of
 c
ho
le
st
er
ol
N
o
N
o
N
o
N
o
N
o
M
en
tio
n 
of
 s
m
ok
in
g
N
o
N
o
N
o
N
o
N
o
St
ud
y 
no
.
6 
[1
7]
7 
[1
8]
8 
[1
9]
9 
[2
0]
10
 [
21
]
Ty
pe
 o
f 
po
pu
la
tio
n
H
H
H
C
H
H
N
N
A
N
A
N
A
N
ot
 p
ro
vi
de
d
N
A
A
ge
,m
ea
n 
ye
ar
s 
(S
D
)
<4
5,
45
–6
9,
>7
0
<4
5,
45
–6
9,
>7
0
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
39
–6
9
N
ot
 c
on
si
de
re
d
Ba
se
lin
e 
D
BP
 m
m
H
g
90
–9
4,
95
–9
9,
10
0–
10
4
90
–9
4,
95
–9
9,
10
0–
10
4
N
o 
fo
cu
s 
on
 D
BP
95
–1
04
,≥
10
5
≥9
3.
5
Ba
se
lin
e 
SB
P 
m
m
H
g
N
o 
fo
cu
s 
on
 S
BP
N
o 
fo
cu
s 
on
 S
BP
18
0
N
o 
fo
cu
s 
on
 S
BP
N
o 
fo
cu
s 
on
 S
BP
M
al
e 
%
G
en
de
r 
di
ffe
re
nc
es
A
ll 
an
al
ys
es
 c
ar
ri
ed
 o
ut
G
en
de
r 
di
ffe
re
nc
es
G
en
de
r 
di
ffe
re
nc
es
N
ot
 c
on
si
de
re
d
ac
co
rd
in
g 
to
 r
is
k 
fa
ct
or
s
se
pa
ra
te
ly
 fo
r 
m
en
 a
nd
ac
co
rd
in
g 
to
 r
is
k 
fa
ct
or
s
ac
co
rd
in
g 
to
 r
is
k 
fa
ct
or
s
ac
co
un
te
d 
fo
r
w
om
en
ac
co
un
te
d 
fo
r
ac
co
un
te
d 
fo
r
R
ac
e 
%
N
ot
 c
on
si
de
re
d
N
ot
 c
on
si
de
re
d
N
ot
 c
on
si
de
re
d
N
ot
 c
on
si
de
re
d
N
ot
 c
on
si
de
re
d
Pr
io
r 
M
I 
%
N
on
e
N
ot
 c
on
si
de
re
d
N
on
e
N
ot
 p
ro
vi
de
d
N
ot
 c
on
si
de
re
d
Ba
se
lin
e 
C
H
D
 %
N
on
e:
Ex
is
tin
g 
LV
H
N
ot
 c
on
si
de
re
d:
ex
is
tin
g 
LV
H
N
on
e
N
ot
 p
ro
vi
de
d
N
ot
 c
on
si
de
re
d
ac
co
un
te
d 
fo
r 
in
 m
od
el
ac
co
un
te
d 
fo
r 
in
 m
od
el
Ba
se
lin
e 
C
V
D
N
ot
 c
on
si
de
re
d
N
ot
 c
on
si
de
re
d
N
on
e
N
ot
 p
ro
vi
de
d
N
ot
 c
on
si
de
re
d
Ba
se
lin
e 
re
na
l d
is
ea
se
N
on
e
N
ot
 c
on
si
de
re
d
N
ot
 c
on
si
de
re
d
N
ot
 p
ro
vi
de
d
N
ot
 c
on
si
de
re
d
M
en
tio
n 
of
 d
ia
be
te
s
G
lu
co
se
 in
to
le
ra
nc
e
G
lu
co
se
 in
to
le
ra
nc
e
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
N
o
M
en
tio
n 
of
 c
ho
le
st
er
ol
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
N
o
M
en
tio
n 
of
 s
m
ok
in
g
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
A
cc
ou
nt
ed
 fo
r 
in
 m
od
el
N
o
A
bb
re
vi
at
io
ns
:B
,b
la
ck
;C
,c
lin
ic
al
 t
ri
al
 p
op
ul
at
io
n 
(r
ea
l p
eo
pl
e;
re
fe
re
nc
e 
to
 o
ri
gi
na
l t
ri
al
 w
as
 p
ro
vi
de
d 
in
 t
he
 C
E 
st
ud
y)
;C
A
BG
,c
or
on
ar
y 
ar
te
ry
 b
yp
as
s 
gr
af
t;
C
H
,c
oh
or
t 
en
ro
lle
d 
in
 a
 c
ar
di
ov
as
cu
la
r 
pr
ev
en
tio
n 
pr
og
ra
m
;C
H
F,
co
ng
es
tiv
e 
he
ar
t 
fa
ilu
re
;D
BP
,d
ia
st
ol
ic
 b
lo
od
 p
re
ss
ur
e;
H
,h
yp
ot
he
tic
al
 p
op
ul
at
io
n;
LV
H
,l
ef
t 
ve
nt
ri
cu
la
r 
hy
pe
rt
ro
ph
y;
O
,o
th
er
;S
BP
,s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e;
T
IA
,t
ra
ns
ie
nt
 is
ch
em
ic
 a
tt
ac
k;
W
,w
hi
te
.
363Comparing CEAs of Anti-Hypertensive Therapy
Ta
bl
e 
2
R
ep
or
te
d 
co
st
-e
ffe
ct
iv
en
es
s 
re
su
lts
,e
nd
 p
oi
nt
s,
tr
ea
tm
en
t 
co
m
pa
ri
so
n,
m
et
ho
d 
of
 d
er
iv
in
g 
be
ne
ﬁt
 m
ea
su
re
,t
re
at
m
en
t 
du
ra
tio
n,
an
d 
fo
llo
w
-u
p 
tim
e 
fo
r 
ev
en
ts
St
ud
y 
no
.
1 
[1
2]
2 
[1
3]
3 
[1
4]
4 
[1
5]
5 
[1
6]
C
os
ts
 p
er
 li
fe
 y
ea
r
$4
,2
62
–$
65
8,
37
0
£2
91
–£
72
0 
(in
cr
em
en
ta
l)
<5
%
 c
ha
nc
e 
th
at
 c
os
t 
$(
8,
23
6)
 s
av
in
gs
–$
1,
66
4
ga
in
ed
>$
3,
00
0
In
cr
em
en
ta
l c
os
t 
pe
r
4 
Sw
ed
is
h 
cr
ow
ns
m
m
H
g 
re
du
ct
io
n
Ev
en
t 
co
st
 s
av
in
g
pe
r 
pe
rs
on
 y
ea
r
C
os
t 
pe
r 
Q
A
LY
$2
,6
60
O
th
er
 b
en
eﬁ
ts
M
I 
av
er
te
d
Ex
tr
a 
ye
ar
s 
fr
ee
 f
ro
m
 e
nd
N
um
be
r 
of
 p
at
ie
nt
s
A
vo
id
ed
 m
or
bi
d 
ev
en
ts
,
po
in
ts
re
ac
hi
ng
 t
ar
ge
t 
D
BP
In
cr
em
en
ta
l m
ed
ic
al
 t
he
ra
py
to
 r
ea
ch
 B
P 
go
al
En
d 
po
in
ts
Fa
ta
l M
I
C
H
D
,c
er
eb
ro
va
sc
ul
ar
m
m
H
G
 r
ed
uc
tio
n
C
om
bi
ne
d 
he
ar
t 
di
se
as
e,
M
I,
st
ro
ke
,h
ea
rt
 f
ai
lu
re
,e
nd
di
se
as
e,
am
pu
ta
tio
n,
la
se
r
ho
sp
ita
liz
at
io
n 
fo
r 
he
ar
t
st
ag
e 
re
na
l d
is
ea
se
,d
ea
th
su
rg
er
y 
fo
r 
re
tin
op
at
hy
,
fa
ilu
re
,d
ea
th
ca
ta
ra
ct
 e
xt
ra
ct
io
n,
re
na
l
fa
ilu
re
,d
ea
th
Tr
ea
tm
en
t
T
hr
ee
 B
P 
re
du
ct
io
n 
ta
rg
et
Tw
o 
BP
 r
ed
uc
tio
n 
ta
rg
et
C
C
B/
BB
 v
s.
A
C
EI
A
C
EI
 v
s.
pl
ac
eb
o
Tw
o 
BP
 r
ed
uc
tio
n 
ta
rg
et
co
m
pa
ri
so
n
gr
ou
ps
gr
ou
ps
le
ve
ls
Tr
ea
tm
en
t 
ef
fe
ct
s
3.
6
M
I/1
,0
00
 p
er
so
n 
ye
ar
s
Ye
ar
s 
fr
ee
 f
ro
m
 e
nd
 p
oi
nt
s
C
C
B/
BB
 =
12
m
m
H
g
0.
81
9 
re
la
tiv
e 
ri
sk
 (
R
R
)
R
R
 =
0.
65
 (
st
ro
ke
),
0.
90
2.
7
M
I/1
,0
00
 p
er
so
n 
ye
ar
s
w
ith
in
 t
ri
al
re
du
ct
io
n
re
du
ct
io
n 
fo
r 
m
or
ta
lit
y
(M
I),
0.
80
 (
ES
R
D
),
2.
6
M
I/1
,0
00
 p
er
so
n 
ye
ar
s
A
C
EI
 =
7.
2
m
m
H
g
R
R
 =
0.
75
 (
he
ar
t 
fa
ilu
re
)
re
du
ct
io
n
H
ow
 t
he
 t
re
at
m
en
t
C
lin
ic
al
 t
ri
al
;m
od
el
ed
 y
ea
rs
C
lin
ic
al
 t
ri
al
;s
im
ul
at
io
n
C
lin
ic
al
 t
ri
al
C
lin
ic
al
 t
ri
al
;s
ta
te
Pu
bl
is
he
d 
st
ud
ie
s;
M
ar
ko
v
ef
fe
ct
 a
nd
 b
en
eﬁ
t
of
 li
fe
 lo
st
m
od
el
 t
o 
es
tim
at
e 
lif
e
tr
an
si
tio
n 
m
od
el
 t
o
m
od
el
 t
o 
es
tim
at
e 
su
rv
iv
al
m
ea
su
re
s 
w
er
e
ex
pe
ct
an
cy
pr
oj
ec
t 
su
rv
iv
al
tim
e
de
ri
ve
d
D
ru
g 
tr
ea
tm
en
t
N
ot
 r
ep
or
te
d
8.
4 
ye
ar
s 
(r
an
ge
 0
–1
0)
8 
w
ee
ks
A
pp
ro
x 
2.
8 
ye
ar
s
N
ot
 r
ep
or
te
d
du
ra
tio
n
Fo
llo
w
-u
p 
tim
e 
fo
r
N
ot
 r
ep
or
te
d
8.
4 
ye
ar
s 
(r
an
ge
 0
–1
0)
4 
an
d 
8 
w
ee
ks
A
pp
ro
x 
2.
8 
ye
ar
s
Li
fe
tim
e
ev
en
ts
(c
on
tin
ue
d)
364 Mullins et al.
Ta
bl
e 
2
co
nt
in
ue
d
St
ud
y 
no
.
6 
[1
7]
7 
[1
8]
8 
[1
9]
9 
[2
0]
10
 [
21
]
C
os
ts
 p
er
 li
fe
 y
ea
r
M
:9
47
,0
00
 S
w
ed
is
h 
cr
ow
ns
M
:$
1,
00
0–
$1
12
,0
00
BB
1:
30
,0
00
–2
4,
00
0
M
:$
31
,5
27
–$
68
,2
46
ga
in
ed
F:
2,
50
6,
00
0 
Sw
ed
is
h 
cr
ow
ns
F:
$0
–$
25
0,
00
0
N
ew
 Z
ea
la
nd
 $
F:
$2
8,
85
8–
$1
26
,9
90
BB
2:
22
,5
00
–1
4,
00
0
N
ew
 Z
ea
la
nd
 $
In
cr
em
en
ta
l c
os
t 
pe
r
m
m
H
g 
re
du
ct
io
n
Ev
en
t 
co
st
 s
av
in
g
C
H
D
:$
45
.7
6
pe
r 
pe
rs
on
 y
ea
rs
St
ro
ke
:$
21
.6
4
C
os
t 
pe
r 
Q
A
LY
$1
,0
00
–$
17
2,
00
0
A
pp
ro
x 
eq
ua
l t
o 
co
st
 p
er
lif
e 
ye
ar
 g
ai
ne
d 
du
e 
to
 
lo
w
 in
ci
de
nc
e 
of
 n
on
fa
ta
l
ev
en
ts
 d
ur
in
g 
5-
ye
ar
tr
ea
tm
en
t 
pe
ri
od
O
th
er
 b
en
eﬁ
ts
En
d 
po
in
ts
C
H
D
,S
tr
ok
e
C
H
D
,s
tr
ok
e,
de
at
h
C
H
D
,c
er
eb
ro
va
sc
ul
ar
M
or
bi
di
ty
 a
nd
 m
or
ta
lit
y
C
H
D
,S
tr
ok
e
ev
en
t,
de
at
h
du
e 
to
 B
P 
le
ve
l
Tr
ea
tm
en
t
C
C
B/
A
C
EI
 v
s.
BB
/d
iu
re
tic
 v
s.
N
/A
BB
1 
vs
.B
B2
C
C
B 
vs
.A
C
EI
 v
s.
BB
 v
s.
A
C
EI
1 
vs
.A
C
EI
2 
vs
.A
R
B
co
m
pa
ri
so
n
pl
ac
eb
o
di
ur
et
ic
Tr
ea
tm
en
t 
Ef
fe
ct
s
BB
/d
iu
re
tic
:R
R
 =
0.
38
A
ll 
tr
ea
tm
en
ts
:R
R
 =
0.
38
SB
P 
re
du
ct
io
n:
BB
1 
=
m
m
H
G
 D
BP
 r
ed
uc
tio
n:
D
BP
 t
ro
ug
h/
pe
ak
 r
at
io
:
(s
tr
ok
e)
,0
.1
6 
(C
H
D
)
(s
tr
ok
e)
,0
.1
6 
(C
H
D
)
14
.4
m
m
H
g
M
ild
 H
T
N
:4
.9
–1
0.
0
55
%
–8
7.
5%
C
C
B/
A
C
EI
:R
R
 =
0.
38
BB
2 
=
16
.0
m
m
H
g
M
od
er
at
e 
H
T
N
:1
3.
4–
Pe
ak
 D
BP
 =
10
m
m
H
g 
fo
r
(s
tr
ok
e)
,0
.2
3 
(C
H
D
)
21
.4
ea
ch
 d
ru
g
H
ow
 t
he
 t
re
at
m
en
t
M
et
a-
an
al
ys
is
:l
og
is
tic
 r
is
k
M
et
a-
an
al
ys
is
:l
og
is
tic
 r
is
k
M
et
a-
an
al
ys
is
:m
od
el
ed
A
pp
lie
d 
Fa
rm
in
gh
am
BP
 p
ea
k 
ra
tio
s 
to
 e
st
im
at
e
ef
fe
ct
 a
nd
 b
en
eﬁ
t
fu
nc
tio
n 
fo
r 
st
ro
ke
 +
C
H
D
fu
nc
tio
n 
fo
r 
st
ro
ke
,C
H
D
pr
ed
ic
tio
n 
of
 5
-y
ea
r
eq
ua
tio
n 
to
 c
oh
or
t 
st
ud
y
BP
 c
on
tr
ol
;m
od
el
ed
 t
he
 r
is
k
m
ea
su
re
 w
er
e
fr
om
 F
ra
m
in
gh
am
 s
tu
dy
an
d 
su
rv
iv
al
 f
ro
m
re
du
ct
io
n 
in
 a
bs
ol
ut
e 
ri
sk
m
or
bi
di
ty
 a
nd
 m
or
ta
lit
y
of
 e
ve
nt
s 
us
in
g 
pu
bl
is
he
d
de
ri
ve
d
Fr
am
in
gh
am
 s
tu
dy
us
in
g 
dr
ug
 d
at
a 
an
d
da
ta
da
ta
Fr
am
in
gh
am
 d
at
a
D
ru
g 
tr
ea
tm
en
t
N
ot
 r
ep
or
te
d
N
ot
 r
ep
or
te
d
5 
ye
ar
s
N
ot
 r
ep
or
te
d
1 
ye
ar
du
ra
tio
n
Fo
llo
w
-u
p 
tim
e 
fo
r
N
ot
 r
ep
or
te
d
N
ot
 r
ep
or
te
d
5 
ye
ar
s
N
ot
 r
ep
or
te
d
6 
to
 2
5 
ye
ar
s 
(m
ea
n 
10
)
ev
en
ts
A
bb
re
vi
at
io
ns
:A
C
EI
,a
ng
io
te
ns
in
 c
on
ve
rt
in
g 
en
zy
m
e 
in
hi
bi
to
r;
A
R
B,
an
gi
ot
en
si
n 
II 
re
ce
pt
or
 a
nt
ag
on
is
t;
BB
,b
et
a 
bl
oc
ke
r;
BP
,b
lo
od
 p
re
ss
ur
e;
C
C
B,
ca
lc
iu
m
 c
ha
nn
el
 b
lo
ck
er
;C
H
D
,c
or
on
ar
y 
he
ar
t 
di
se
as
e;
D
BP
,d
ia
st
ol
ic
 b
lo
od
 p
re
s-
su
re
;E
SR
D
,e
nd
-s
ta
ge
 r
en
al
 d
is
ea
se
;F
,f
em
al
e;
H
T
N
,h
yp
er
te
ns
io
n;
M
,m
al
e;
M
I,
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
Q
A
LY
,q
ua
lit
y-
ad
ju
st
ed
 li
fe
 y
ea
r;
SB
P,
sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e.
365Comparing CEAs of Anti-Hypertensive Therapy
Ta
bl
e 
3
St
ud
y 
pe
rs
pe
ct
iv
es
,c
os
t 
co
m
po
ne
nt
s,
co
st
 d
at
a 
so
ur
ce
,d
is
co
un
tin
g 
an
d 
us
e 
of
 s
en
si
tiv
ity
 a
na
ly
si
s
St
ud
y 
no
.
1 
[1
2]
2 
[1
3]
3 
[1
4]
4 
[1
5]
5 
[1
6]
Pe
rs
pe
ct
iv
e
So
ci
et
al
 (
di
re
ct
 c
os
ts
 o
nl
y)
T
hi
rd
-p
ar
ty
 p
ay
er
T
hi
rd
-p
ar
ty
 p
ay
er
T
hi
rd
-p
ar
ty
 p
ay
er
T
hi
rd
-p
ar
ty
 p
ay
er
C
os
t 
co
m
po
ne
nt
s
D
ru
gs
,o
fﬁ
ce
 v
is
its
,
D
ru
gs
,h
om
e 
vi
si
ts
,h
os
pi
ta
l
D
ru
gs
D
ru
gs
,h
os
pi
ta
l
D
ru
gs
,i
np
at
ie
nt
 c
ar
e,
nu
rs
in
g 
ho
m
e
la
bo
ra
to
ry
 w
or
k
So
ur
ce
 o
f 
co
st
 d
at
a
A
ve
ra
ge
 d
ru
g 
w
ho
le
sa
le
Tr
ia
l c
en
te
rs
,B
ri
tis
h
Tr
ia
l r
es
ou
rc
e 
us
e
U
ni
t 
co
st
s 
fr
om
 t
ri
al
,f
ed
er
al
Fe
de
ra
l r
ei
m
bu
rs
em
en
t 
ra
te
s,
pr
ic
e,
pu
bl
is
he
d 
st
ud
ie
s
go
ve
rn
m
en
t
(c
al
cu
la
te
d)
re
im
bu
rs
em
en
t 
ra
te
s,
su
rv
ey
s
an
nu
al
 c
os
ts
 f
ro
m
 o
th
er
 s
tu
di
es
D
is
co
un
tin
g 
(c
os
ts
/
N
o 
/ Y
es
3%
 a
nd
 6
%
 fo
r 
bo
th
N
o 
/ 
N
o
5%
 /
 5
%
5%
 /
 5
%
ef
fe
ct
iv
en
es
s)
Se
ns
iti
vi
ty
 a
na
ly
si
s
N
o
A
lte
rn
at
iv
e 
di
sc
ou
nt
 r
at
es
A
lte
rn
at
e 
dr
ug
 p
ri
ce
s
A
lte
rn
at
iv
e 
tr
ea
tm
en
t 
co
st
s 
an
d
A
lte
rn
at
iv
e 
ag
es
 a
t 
w
hi
ch
 p
at
ie
nt
s
an
d 
no
.o
f 
of
ﬁc
e 
vi
si
ts
di
sc
ou
nt
 r
at
es
 a
t 
2%
 a
nd
 7
%
in
iti
at
ed
 t
re
at
m
en
t
St
ud
y 
no
.
6 
[1
7]
7 
[1
8]
8 
[1
9]
9 
[2
0]
10
 [
21
]
Pe
rs
pe
ct
iv
e
So
ci
et
al
So
ci
et
al
Li
m
ite
d 
so
ci
et
al
 (
di
re
ct
N
ot
 s
ta
te
d 
(d
ir
ec
t 
co
st
s 
on
ly
)
T
hi
rd
-p
ar
ty
 p
ay
er
co
st
s 
on
ly
)
C
os
t 
co
m
po
ne
nt
s
D
ru
gs
,c
on
su
lta
tio
ns
,t
ra
ve
l
D
ru
gs
,c
on
su
lta
tio
ns
,t
ra
ve
l
D
ru
gs
,c
on
su
lta
tio
ns
,
D
ru
gs
,o
fﬁ
ce
 v
is
its
,l
ab
or
at
or
y
D
ru
gs
,c
os
ts
 p
er
 e
ve
nt
an
d 
tim
e,
pr
od
uc
tiv
ity
an
d 
tim
e,
m
or
bi
di
ty
,
ou
tp
at
ie
nt
 v
is
its
,
an
d 
sc
re
en
in
g 
te
st
s
lo
ss
es
su
rg
er
y 
an
d 
di
ag
no
st
ic
s,
am
bu
la
nc
e,
co
st
s
in
cr
ea
se
d 
he
al
th
ca
re
pe
r 
ev
en
t,
ho
sp
ita
l
co
st
s,
pr
od
uc
tio
n 
lo
ss
es
,
st
ay
,r
eh
ab
ili
ta
tio
n
ne
t 
co
ns
um
pt
io
n
So
ur
ce
 o
f 
co
st
 d
at
a
Pu
bl
is
he
d 
st
ud
ie
s
Pu
bl
is
he
d 
st
ud
ie
s,
Sw
ed
is
h
N
ew
 Z
ea
la
nd
 u
ni
t 
dr
ug
Sp
an
is
h 
so
ci
al
 s
ec
ur
ity
 s
ys
te
m
D
ru
g 
w
ho
le
sa
le
 p
ri
ce
,p
ub
lis
he
d
la
bo
r 
de
pa
rt
m
en
t,
pa
yr
ol
l
co
st
s,
pu
bl
is
he
d 
st
ud
ie
s
st
ud
ie
s
ta
x
D
is
co
un
tin
g 
(c
os
ts
/
5%
 /
 5
%
3%
 /
 3
%
5%
 /
 5
%
5%
 /
 5
%
N
o 
/ 
N
o
ef
fe
ct
iv
en
es
s)
Se
ns
iti
vi
ty
 a
na
ly
si
s
N
o
A
lte
rn
at
iv
e 
as
su
m
pt
io
ns
U
se
d 
di
sc
ou
nt
 r
at
e 
at
N
o
A
lte
rn
at
iv
e 
ev
en
t 
co
st
s
ab
ou
t 
tr
ea
tm
en
t 
be
ne
ﬁt
11
.4
%
co
st
s 
an
d 
qu
al
ity
 o
f 
lif
e
366 Mullins et al.
sources outside the trial. The remaining studies all
derived their cost information from a variety of
sources, including published studies and govern-
ment reports.
Eight studies used a third-party payer perspective
and included only direct health-care costs, which
usually are the costs of drugs, ofﬁce visits, labora-
tory tests and hospital admissions (Table 3)
[12–16,19–21]. Some studies included only a subset
of these direct cost variables. STUDY9 [20] did not
state the perspective and STUDY8 [19] stated its
perspective as a limited societal perspective, as the
direct costs paid by the government and the patients
themselves were included. STUDY4 [15] stated that
societal costs were evaluated, as the costs were
derived solely from federal reimbursement agencies.
However, the cost variables included in the study
implied that the perspective was that of a third
party payer.
Two studies used the societal viewpoint and
included productivity loss, measured by income, 
for the indirect cost component [17,18]. One of the
studies also considered increased health-care costs
due to morbidity as part of the indirect costs and
included future costs in terms of increased con-
sumption net of production [18]. Of the 10 studies,
three did not discount the costs, which is reason-
able for both STUDY3 [14] and STUDY10 [21]
since the duration of follow up was short (Table 2)
[12,14,21]. The majority of studies included sensi-
tivity analyses, either by varying the costs or the
treatment effects or by varying the discount rates,
as indicated in Table 3.
Reporting the Cost-Effectiveness Ratio (CER)
As shown in Table 2, most cost-effectiveness studies
expressed cost-per-life-year-gained (saved) results as
the outcome measure [12,13,15–20]. Two studies
considered the incremental cost of clinical-related
outcomes such as mmHg blood pressure reduction
or extra year free from end points [13,14]. Other
noted outcome measures were: cost per avoided
morbid events [16]; cost of incremental medical
therapy to achieve lower blood pressure goals [16];
event-reduction cost savings [21]; and costs per
quality-adjusted life year [15,18,19]. Several studies
provided multiple outcome measures [13–16,18].
The end points included in the analysis varied
greatly across studies. Most studies included coro-
nary heart disease, stroke and death as end points
[13,16,18,19]. In addition to cardiovascular and
cerebrovascular events, some studies included renal
failure, end stage renal disease and heart failure as
end points. STUDY2 [13] also extended the number
of end points by including amputation, laser treat-
ment for retinopathy and cataract extraction.
STUDY9 [20] did not specify the actual end points
other than “morbidity and mortality according 
to high blood pressure.” While STUDY1 [12] only
included death in terms of fatal myocardial infarc-
tion as the end point, STUDY6 [17] and STUDY10
[21] excluded death but included coronary heart
disease and stroke. Only STUDY4 [15] included
hospitalization for heart failure and a measure con-
sisting of a number of ischemic events as end points.
STUDY3 [14] used mmHg-reduced blood pressure
during the trial period and a treatment target of
diastolic blood pressure less than 90mmHg as end
points. Table 2 also presents the cost-effectiveness
results and the drug comparisons performed within
each study.
Discussion
Our ﬁndings stress that there is little method-
ological consistency across cost-effectiveness studies
evaluating pharmacotherapy for the management 
of hypertension. There clearly exists a disparity
between the approach and format that indicates a
need for tighter comparison across studies. Studies
considered different end points, and the methodol-
ogy used to measure effectiveness, the cost variables
included, and the characteristics of the patient 
population varied signiﬁcantly across studies. Due
to this lack of uniformity, it is difﬁcult, if not impos-
sible, to compare the results and draw conclusions
about the relative cost-effectiveness of different
types of drug therapies. This lack of comparability
between studies is likely to elicit criticism from both
the clinical and health-care decision-making com-
munities, and is likely to undermine the argument
supporting wider use of cost-effectiveness analyses
in health-care decision making. In the following 
sections we explore the major points that emerged
from our research ﬁndings as they relate to the 
viability of economic evaluations in health-care
decision making, although the issues discussed are
not relevant to every study included in this review.
Patient Population
The modeled population considered in economic
evaluations must reﬂect a population in a natural-
istic health-care setting to ensure practicability and
generalizability of results. Pharmaceutical beneﬁt
management (PBM) companies support the princi-
ple that relevant populations in CEA make the
analysis more useful for formulary decision making
[6]. Limitations to the generalizability of economic
367Comparing CEAs of Anti-Hypertensive Therapy
studies are more often due to the clinical design of
the studies, namely patient inclusion and exclu-
sion criteria, than to methodological ﬂaws in the
economic analysis. Therefore, generalizability of 
the study to other patient populations should be
addressed either by using modeling or by address-
ing the issue as part of the discussion.
When performing economic evaluations of 
subpopulations deﬁned in terms of gender, race, age
groups, and/or the presence of certain comorbid-
ities, researchers should, to the extent possible,
present the results in the same context as the full
analysis. Sub-analyses usually compare the beneﬁts
of one agent vs. another in a selected group of
patients, which is a legitimate and valid method.
However, the end points should generally be con-
sistent with the ones used when the analysis is
applied to the general population (i.e., measured 
in terms of reduction in a consistent set of major
end points – cardiovascular, stroke, or renal events).
For this reason, subanalysis should conform to 
the overall analyses to make comparability across
studies meaningful. In turn, this procedural recom-
mendation should not be construed as restricting
the evaluation of a particular antihypertensive agent
for the purposes of showing superiority over other
agents in terms of a speciﬁc end point. For example,
angiotensin converting enzyme (ACE) inhibitors
have been documented as being superior to other
antihypertensive agents in terms of renal protective
effects in hypertensive, diabetic patients. While
cost-effectiveness analysis in this case is legiti-
mate and quite valuable, conducting the cost-
effectiveness analysis as a subanalysis should
address the issues relevant to general hypertensive
patients as well; namely, the cost components, out-
comes, and appropriate drug comparators. Other-
wise, the authors should be very clear and direct
about the lack of generalizability of their results.
Despite the fact that isolated SBP is a better 
predictor of cardiovascular and cerebrovascular
outcomes as compared to isolated DBP [22], the
majority of studies deﬁned hypertension in terms of
diastolic blood pressure and used baseline diastolic
blood pressure as an inclusion criterion. This may
be due in part to the fact that the importance of SBP
is a rather recent ﬁnding. Nevertheless, future
studies should address both the SBP and the DPB
when deﬁning hypertension and the inclusion crite-
ria for clinical trials.
Cost Components
As presented in Table 3, cost components vary sig-
niﬁcantly across the studies and many studies
pooled economic data from multiple study sites 
or federal reimbursement sites. This methodology
could pose a problem if appropriate adjustments are
not made, since practice patterns differ among
providers according to their site (rural, suburban or
urban), and according to whether it is the Veterans’
Administration or a managed care setting or
whether costs are derived directly from clinical
trials [23].
STUDY2 [13] addressed the issue of resource uti-
lization by considering resources driven by the trial
protocol and resources driven by standard clinical
practice. The problem with using divergent sources
becomes even more serious when cost data are col-
lected from different countries, as currency conver-
sions add to the uncertainty [23]. STUDY7 [18] and
STUDY9 [20] converted cost estimates into US
dollars from Swedish Crowns and Spanish Pesetas,
respectively. To minimize the uncertainty associated
with health-care utilization, improved methods for
estimating variance in resource utilization are
required [23]. Sensitivity analysis that accounts 
for the variation in expenditures for health-care 
services is one method available for testing how 
the variability in utilization affects the cost-
effectiveness of the treatment. Some methods used
to translate cost estimates across countries include
the use of exchange rates, purchasing power parity
and discount rates, or price indexes when the time
period differs across studies.
Economic evaluations in most of the studies were
conducted from a payer perspective and considered
only direct costs (Table 3). All relevant direct costs
such as drugs, ofﬁce visits and hospitalizations were
usually included. Direct costs such as emergency
room visits and nursing time that were not included
should perhaps be considered in future studies to
achieve a more thorough and accurate representa-
tion [23]. Only a few studies considered indirect
costs, which are important both to the patient and
to society. Furthermore, it is essential to include
indirect costs in hypertension studies to capture all
the relevant areas that a drug treatment may affect.
In terms of therapeutic interventions for hyperten-
sion, whenever a hospital admission is prevented,
the treatment also diminishes productivity losses,
which the patient would have experienced due to
absenteeism from work or reduced productivity
while at work [24].
None of the studies considered the costs of
switching from one drug or class of antihyperten-
sive pharmacotherapy to another. Only one study
accounted for costs due to side-effects [16].
STUDY5 [16] described an increase in the cost per
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life year saved in direct proportion to the increased
likelihood of an adverse event, or an increase in 
the ultimate costs of adverse events. However, the
authors stated that they did not include additional
costs for hospitalization and/or injuries due to
adverse reactions, since those occurrences are very
rarely associated with current antihypertensive
drugs. These costs may be captured when treatment
costs are derived fully or partially from the clinical
trial. Poor compliance may also be associated with
higher health-care costs [16,25]. Rizzo et al. [25]
examined compliance rates for four major antihy-
pertensive drug classes and the health-care costs
associated with noncompliance. Compliance rates
varied between drug classes, and poor compliance
was associated with higher health-care costs [25].
In future studies it may be important to consider
compliance, as suggested by Roth et al. [21], since
poor compliance with pharmacotherapy is a very
common phenomenon among antihypertensive
patients.
Outcomes (End Points)
Although the end points included in the economic
evaluations varied across studies, the majority of
studies used a variety of hard clinical end points as
the primary outcome, suggesting that a certain con-
sensus has been achieved in terms of including 
cardiovascular and cerebrovascular events. Only
two studies considered renal events as end points,
speciﬁcally in the case of hypertensive-diabetic
patients. Reducing blood pressure can, naturally,
reduce the occurrence of both events contingent on
the length of follow-up. Nonetheless, these hard
clinical end points should be the ultimate goal and
focus of economic analyses, rather than the reduc-
tion in blood pressure itself. The fact that the
studies use diverse end points and approaches to
calculate cost-effectiveness should not be attributed
to ﬂawed or faulty methodology, but rather, as evi-
dence that pharmacoeconomic evaluations lack
methodological consistency, particularly in the case
of antihypertensive treatments. This reduces the
utilitarian value of the results of these evaluations
for health-care decision making. One way to
address this issue is to deﬁne a priori primary and
secondary outcomes of the CEA.
While we did not speciﬁcally address the differ-
ences in risk functions used and their consequences
for the pharmacoeconomic outcomes presented
here, it is worth stating that the studies also applied
different statistical methods. Some have used log
risk functions and clinical trial information
(Table 2), while others used Weibull models. This
complicates the comparison of pharmacoeconomic
outcomes unless the authors speciﬁcally address
such issues in their study.
Since most hypertension studies are of a short
duration, the long-term beneﬁts are often modeled.
In the process of model development, it is impor-
tant that uncertainties and assumptions are clearly
stated [26]. The majority of studies used modeling
to extend treatment beneﬁt beyond the duration of
the respective clinical trials. However, the informa-
tion presented in some of the studies lacked the
transparency necessary for the reader to determine
whether the methods used were appropriate and
whether the assumptions made were sound. For
example, STUDY9 [20] mentioned that the effec-
tiveness term of life year gained was estimated using
the Framingham equation without describing the
method. Likewise, the study did not address the
duration of antihypertensive treatment from which
the treatment effect is projected. Similarly, in
STUDY1 [12] it is unclear how the net years of life
gained were converted into disability-adjusted life
years and further translated into cumulative dis-
ability-adjusted life years. Contrary to these exam-
ples, studies such as STUDY2 [13] and STUDY4
[15] clearly explain how they deﬁned the treatment
beneﬁt and the method used to estimate life
expectancy (Table 2). It is important that methods
and assumptions be clearly presented so that deci-
sion makers can be conﬁdent when applying these
results to their health-care system.
Modeling Long-Term Outcomes
Hay et al. [26] strongly recommended that model-
ing of costs and effectiveness attain greater recog-
nition as a valid and often essential component of
health-care decision making. In chronic diseases
such as hypertension, outcome events such as com-
plications of the disease or its treatment, recurrence
of disease and mortality are often confounded with
probabilities that change with time during a life-
time, such as age and health status. Thus, models
that allow for a change in the risk of outcomes over
time may be more informative and realistic.
Appropriate Drug Comparator
Multi-drug comparison is also expressed by PBM’s
as a need for economic evaluations [6]. It is widely
accepted that lowering blood pressure reduces the
risk of cardiovascular, cerebrovascular, and renal
events. If health-economic evaluations of treatments
for hypertension are to be useful for decision
making, the evaluations should shift the focus from
prevention of clinical end points by any drug to the
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economic consequences of preventing clinical end
points by a number of speciﬁc comparable drugs.
Four studies compared the cost-effectiveness across
two or more speciﬁc antihypertensive drugs
[14,19–21]. In STUDY4 [15] drug-placebo com-
parison was performed, whereas STUDY6 [17]
compared several antihypertensive drug categories
such as ACE inhibitors plus calcium antagonists to
beta blockers plus diuretics. The remaining studies
did not consider a speciﬁc treatment but rather,
examined the fact that drug treatment reduces
blood pressure and thereby reduces the risk of spe-
ciﬁc clinical end points. Drug comparisons either
within each of the antihypertensive drug classes 
or across the drug classes would be useful for the
decision-making process.
Summary and Recommendations
Management of hypertension, regardless of the spe-
ciﬁc therapy, is targeted toward reducing the long-
term outcomes, most importantly cardiovascular,
cerebrovascular and renovascular events. It is true
that all studies are conducted with different patient
populations in terms of the inclusion and exclusion
criteria, but all studies are performed on patients
with hypertension stages I, II, and/or III. Alterna-
tively, subanalyses can be performed on each patient
subpopulation. Finally, a combination of modeling
and subpopulation analysis can be applied, while
accounting for the probabilities of the different 
end points among the different populations. Cost-
effectiveness studies of antihypertensive therapies
should maintain their focus on these primary out-
comes. To the extent that other positive attributes,
such as a more favorable side-effect proﬁle, are con-
sidered, they should be viewed in the context of the
primary objective of reducing cardiovascular events.
It is helpful to examine speciﬁc subpopulations
of hypertensive patients, which may offer additional
guidance to clinicians and other decision makers.
When subgroups such as diabetic-hypertensive
patients with elevated systolic hypertension, or a
speciﬁc race or gender is examined, modeling tech-
niques can be used to address these subgroups. 
Sub-analyses can be performed on each patient sub-
population, or a combination of these two methods,
while accounting for the probabilities of the differ-
ent end points among the different patient popula-
tions, can be applied. Again, subpopulation analysis
should not focus on one isolated facet of hyperten-
sion management without addressing the broader
concerns of general hypertension management,
unless the agent is going to be indicated only for
that speciﬁc particular aspect.
Determining which cost components to include
and how to measure them is difﬁcult. Variation may
exist across patient populations or clinical practice
settings. In most European countries for example,
laboratory or diagnostics costs are included in 
the visit or hospitalization costs. Consequently, the 
cost components could be simpliﬁed into categories
that are common to all drug classes. These common
categories include: hospitalizations; physician ser-
vices; ofﬁce visits; emergency room visits; labora-
tory/diagnostics; drug costs (accounting for realistic
compliance and switch therapy), and adverse
events.
If economic analyses are performed while
keeping in mind the issues described above, one can
see that the analyses will then be more comparable.
Decision makers can make more valid judgments as
to the viability of a particular economic evaluation
or the credibility of results. What was not ade-
quately addressed herein is how to report the 
cost-effectiveness ratio. Certain jurisdictions require
certain types of economic evaluations (e.g., cost-
utility analysis in addition to cost-effectiveness
analysis in Canada), but we recommend that eco-
nomic evaluations should be performed to assist
clinical and health-care policy decision making.
Cost-effectiveness analysis should focus on the most
relevant outcomes for decision making, rather than
simply highlighting those aspects that make the
investigational drug look the best.
The Panel on Cost-Effectiveness in Health and
Medicine recently published a list of detailed 
recommendations for conducting health economic
analysis [1]. In their recommendations, the panel
considered a variety of different methodological
techniques to improve the quality of future analy-
ses and to encourage comparability across studies
in general. Taking a different approach than the
panel, this review highlights methodological dis-
crepancies identiﬁed in cost-effectiveness analyses
of antihypertensive agents. The following recom-
mendations are therefore hypertension-speciﬁc but
are considered to be consistent with the general 
recommendations provided by the panel:
• Cost-effectiveness analysis should be rigorous
and useful for decision making.
• Short run outcomes should include systolic and
diastolic blood pressure.
• Long-term outcomes should include, as appro-
priate, myocardial infarction, stroke, congestive
heart failure and renal events depending on the
length of follow-up. Long-term renal events may
be useful only for very high-risk patients, as data
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concerning the relationship of hypertension and
renal events are scarce.
• Other positive attributes, such as a more favor-
able side-effect proﬁle, should enhance (not
replace) the long-term outcomes.
• When subpopulations are considered in submod-
els, studies should address limitations and gener-
alizability issues.
• Modeling is an acceptable method provided 
that data sources and assumptions are valid and
transparent.
• Cost calculations should be transparent and
related to the perspective of the study.
Conclusion
Cost-effectiveness analyses should continue to be
performed to address the economic impact of 
antihypertensive agents on this very costly disease.
However, varying the methods used to estimate
cost-effectiveness as a means for differentiating
these agents is not appropriate and should not 
be confused with performing appropriate cost-
effectiveness analyses to highlight true differences 
in product attributes. If different antihypertensive
agents vary in their impact on the same long-term
outcome, this should be highlighted in economic
evaluations. In light of such disparity, economic
analyses should be performed appropriately to aid
the clinical and health-care policy decision-making
process. If this is accomplished, we, as health ser-
vices researchers, will feel secure knowing that our
mission is possible and is beneﬁcial to other health-
care providers
Funding for this study was provided by Pharmacia.
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